Illumina said it wrapped up the $7.1 billion acquisition of life-sciences firm Grail, despite a legal battle with the Federal Trade Commission and antitrust concerns in Europe.
Read More
Illumina said it wrapped up the $7.1 billion acquisition of life-sciences firm Grail, despite a legal battle with the Federal Trade Commission and antitrust concerns in Europe.
Read More